Survey Among Healthcare Professionals and MS Patients to Assess Their Understanding of RMP Materials
NCT ID: NCT05301907
Last Updated: 2025-12-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
335 participants
OBSERVATIONAL
2021-12-02
2025-05-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Health Care Professionals (HCPs)
HCPs who prescribe, monitor and oversee the management / or provide in person medical supervision of patients on Mayzent (siponimod).
No interventions assigned to this group
Patients/Caregivers
Patients/Caregivers of patients who are taking Mayzent (siponimod) to treat their MS and according to the prescription of their neurologists across EU countries and Canada that were included in the launch program
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Care for relapsing MS (RMS) patients
* Personally prescribed disease modifying therapies to MS patients, and;
* Have prescribed Mayzent (siponimod) in at least 1 SPMS patient.
Nurses were considered eligible for the survey if they:
* Provide supportive care for RMS patients
* Have initiated and/or managed the use of Mayzent (siponimod) in at least 1 SPMS patient.
\- Had initiated onto Mayzent (siponimod) to treat their MS since reimbursement
Exclusion Criteria
18 Years
100 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Novartis Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Novartis Investigative Site
Basel, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Link to study results
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EUPAS44782
Identifier Type: OTHER
Identifier Source: secondary_id
CBAF312A2006
Identifier Type: -
Identifier Source: org_study_id